GlassScriptPhysician profile
Arek J Wiktor
NPI 1720203383
$3,575.12
in general payments reported to CMS, 2019-2025
8 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.23 · 2022: $798 · 2023: $991 · 2024: $1,131 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $1,463.85 | 2022-2025 | Novosorb Btm |
| Avita Medical Americas, LLC | $738.74 | 2019-2025 | Recell, Permeaderm, Cohealyx |
| Integra Lifesciences Corporation | $555.58 | 2022-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $301.36 | 2022-2023 | Collagenase Santyl |
| Acera Surgical, INC. | $222.53 | 2024-2025 | Restrata Wound Matrix |
| Vericel Corporation | $166.33 | 2023 | Epicel (Cultured Epidermal Autografts) |
| Astrazeneca Pharmaceuticals LP | $88.99 | 2024 | Andexxa |
| La Jolla Pharmaceutical Company | $37.74 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arek Wiktor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.